Explore the evolving treatment landscape in acute myeloid leukemia (AML). Expert thought leaders provide details into FLT3-mutation and IDH1/2-mutation inhibitors, antibody therapy, and the role of minimal residual disease (MRD) in AML.
This activity also includes a downloadable resource on the safety issues of two of the most recent agents approved to treat AML; glasdegib and venetoclax. Click here to download the adverse events handout.
1.0 AMA PRA Category 1 Credit(s)™
Apr 15, 2019
Apr 15, 2020
Mark J. Levis, MD, PhDSidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland, United States
Eytan M. Stein, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
- FLT3 mutation inhibitors
- IDH inhibitors
- New/emerging agents
- MRD assessment in AML
This activity is designed to meet the educational needs of hematologists, medical oncologists, midlevel providers, nurses, and other healthcare providers who treat and/or manage patients with AML.
After successful completion of this educational activity, participants should be able to:
- Describe safety and efficacy data from recently approved targeted agents for AML
- Incorporate strategies for the detection and management of toxicities related to the treatment of AML
- Discuss the role and appropriate timing for MRD assessment in the treatment for patients with AML
This educational activity is supported by a grant from AbbVie.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1 hour
To contact Postgraduate Institute for Medicine, please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Levis has disclosed that he has received consulting fees from Agios, Amgen, Astellas, Daiichi-Sankyo, Karyopharm, and Novartis Oncology. He has also performed contracted research for Astellas, FujiFilm, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Stein has disclosed that he has received consulting fees for membership on advisory boards from Agios; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Novartis Oncology; and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine planners and managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer
- Briana Betz, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
- Susan McKinney – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.